In a filing, Blueprint Medicines Corp revealed its CHIEF SCIENTIFIC OFFICER Carter Percy H. unloaded Company’s shares for reported $0.34 million on Jun 03 ’25. In the deal valued at $127.88 per share,2,659 shares were sold. As a result of this transaction, Carter Percy H. now holds 54,206 shares worth roughly $6.95 million.
Then, Albers Jeffrey W. sold 5,000 shares, generating $505,692 in total proceeds. Upon selling the shares at $101.14, the Director now owns 146,630 shares.
Before that, Albers Jeffrey W. bought 5,000 shares. Blueprint Medicines Corp shares valued at $505,686 were divested by the Director at a price of $101.14 per share.
Wedbush downgraded its Blueprint Medicines Corp [BPMC] rating to a Neutral from a an Outperform in a research note published recently. Wolfe Research began covering BPMC with “an Outperform” recommendation on March 18, 2025. Jefferies started covering the stock on March 17, 2025. It rated BPMC as “a Buy”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 0.23% to $128.25. Over the last five days, the stock has gained 0.22%. Blueprint Medicines Corp shares have risen nearly 47.04% since the year began. Nevertheless, the stocks have risen 20.83% over the past one year. While a 52-week high of $128.34 was reached on 06/11/25, a 52-week low of $73.04 was recorded on 04/09/25.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 127.97, which if violated will result in even more drops to 127.69. On the upside, there is a resistance level at 128.42. A further resistance level may holdings at 128.58.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $150 price target.
